Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1-8 and 10-21 are pending.
Claims 6 and 18 are withdrawn.
Priority
Applicant’s claim for benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. This application is a national stage entry of and claims priority to Application Serial No. PCT/EP2021/066558, filed 6/18/2021; and further claims priority to foreign application EP20180838.3, filed 6/18/2020.
Information Disclosure Statement
All references from IDS(s) received 12/16/2022 and 03/15/2023 have been considered unless marked with a strikethrough.
Response to Arguments
Applicant’s arguments filed 6/18/2026, with respect to the rejections of claims 1-5, 7-17, and 19-20 under 35 U.S.C. 103 and nonstatutory double patenting have been fully considered and are found not persuasive.
The Applicant amended claim 1 to recite:
PNG
media_image1.png
482
536
media_image1.png
Greyscale
With respect to the 103 rejection, the Applicant argues that the primary reference cited by the Examiner (“Hwang”) fails to teach aryl based calix(n)arenes in the treatment of respiratory viruses. Rather, the Applicant points out that only naphthyl-based compounds are used by Hwang for respiratory viruses while the aryl-based compounds are used for non-respiratory viruses. The Examiner agrees with the Applicant that this is what Hwang teaches. Since the applicant amended claim 1 to specify only aryl-based calixarenes, the Examiner agrees that Hwang does not apply. However, in light of the amendment, the Examiner introduces new art that is anticipatory of the independent claim.
With respect to the double patenting rejections, the Applicant has provided evidence that the overlapping method has been struck through in the other application. Therefore, this rejection is moot and withdrawn.
The declaration under 37 CFR 1.132 filed 6/18/2026 is insufficient to overcome the rejection of claims based upon U.S.C. 103 as set forth in the last Office action because: Applicant has provided an affidavit explaining that the elected species (used interchangeably as CAL-4 or CX-1) shows unexpected results in respiratory diseases. The Examiner does not find most of these results persuasive. First, the Applicant shows data that 500 uM of CAL-4 improves the active cilia area in the H1N1 virus in comparison to the control and another antiviral drug, Oseltamivir (Fig 1, Affidavit). In contrast, The Examiner points out that other data in the application shows that the other antiviral is significantly improved in decreasing H1N1 copy number (Fig 4, Drawings/Spec). Also, the Applicant does not provide any literature to compare either of these results. Second, the new art provided by the Examiner teaches that the elected species has less than desirable effects against coronavirus (Geller) and influenza (Tauran) in comparison to other calix(n)arenes. Therefore, the Examiner does not find the data provided by the Applicant persuasive. See new rejections below. Since the art of the new rejections were not previously included this action is SECOND NON-FINAL.
NEW/MAINTAINED REJECTIONS
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-3, 10, and 14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Geller, C. et al. (Antiviral Research 88 (2010) 343–346; cited in IDS filed 3/15/2023; “Geller”).
This rejection applies to the elected species of compound, however the elected species of disease has been expanded to any coronavirus.
PNG
media_image2.png
172
318
media_image2.png
Greyscale
Geller teaches a structural example of the elected species (Fig. 1 left compound) for the use in treating coronavirus, specifically HCoV229E.
Therefore, the limitations of claims 1-3, 10, and 14 are anticipated by Geller.
Claims 1-4, 10, and 14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Tauran, Y. et al. (Antibiotics (Basel). 2019 Jun 3;8(2):73.; cited in IDS filed 3/15/2023; “Tauran”).
This rejection applies to the elected species of compound, however the elected species of disease has been expanded to influenza.
PNG
media_image2.png
172
318
media_image2.png
Greyscale
Tauran teaches a structural example of the elected species (Scheme 1, “SC4a”) for the use in treating influenza, specifically H3N2.
Therefore, the limitations of claims 1-4, 10, and 14 are anticipated by Tauran.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-5, 7-8, 10-17, and 19-21 are rejected under 35 U.S.C. 103 as being unpatentable over Hwang, K. (WO1994003164A1; cited in IDS filed 3/15/2023; “Hwang”) in further view of Tauran, Y. et al. (Antibiotics (Basel). 2019 Jun 3;8(2):73.; “Tauran”) and Geller, C. et al. (Antiviral Research 88 (2010) 343–346; “Geller”).
Hwang teaches calixarene compounds for the treatment of enveloped viruses, such as influenza A. Hwang explicitly teaches an example of the elected specie (Figure 8, Compound Y-1) also with a pharmaceutically acceptable carrier (page 70, line 9), as required by instant claims 1, 2, 4, 5, 9, 10, 15, and 17.
Hwang also teaches the compounds for topical or inhalation administration (Page 9, line 31-33) in the form of liquid or tablet (Page 10, lines 10-14), as required by instant claims 8, 11, 12, 16, and 20.
Hwang also teaches the compound in combination with an additional antiviral compound (page 70, line 11-13), as required by instant claims 14 and 19.
Finally, Hwang teaches the dosage form to be a composition that is pharmaceutically effective, i.e. effective to inhibit viral infection of host cells (page 70, line 14-23), as required by claim 7.
With respect to claim 13, Hwang fails to explicitly teach administration of the antiviral of an amount of 1-100ug per nostril. However, Hwang does teach administration of the compound in a range of 0.1 ug to 100ug/mL and also teaches it can be done through inhalation administration. This is considered an overlapping range with instant claim 13. Therefore, in the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In reWoodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990).
Hwang fails to explicitly teach examples using aryl-based calix(n)arenes in influenza virus or coronavirus, as required by instant claims 2 and 21, respectively.
However, Tauran teaches a structural example of the elected species (Scheme 1, “SC4a”) for the use in treating influenza, specifically H3N2. Further, Geller teaches a structural example of the elected species (Fig. 1 left compound) for the use in treating coronavirus, specifically HCoV229E.
Therefore, it would be obvious to a person skilled in the art at the time to extract the method of treating respiratory diseases with calix(n)arenes and use the elected species to treat influenza or coronavirus.
The Supreme Court in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper "functional approach" to the determination of obviousness as laid down in Graham.
Examples of rationales that may support a conclusion of obviousness include:
(A) Combining prior art elements according to known methods to yield predictable results;
(B) Simple substitution of one known element for another to obtain predictable results;
(C) Use of known technique to improve similar devices (methods, or products) in the same way;
(D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results;
(E) "Obvious to try" – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success;
(F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art;
(G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention.
Applying KSR example rationale (B), it would have been prima facie obvious to extract the method of using a calixarene as an antiviral, as taught by Hwang, and use the aryl-based calix(n)arene, such as the elected specie, and use it in a respiratory virus, such as influenza or coronavirus, as taught by Tauran and Geller.
Therefore, claims 1-5, 7-8, 10-17, and 19-21 would have been obvious to a person skilled in the art at the time.
Conclusion
Claims 1-5, 7-8, 10-17, and 19-21 are rejected.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to NICOLA MARIA BAUER whose telephone number is (703)756-1269. The examiner can normally be reached Monday-Friday 7:30-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clint Brooks can be reached at (571) 270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/N.M.B./Examiner, Art Unit 1621
/CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621